Live Breaking News & Updates on Immune Mediated Inflammatory
Stay updated with breaking news from Immune mediated inflammatory. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 1
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121
Takeda TSE4502NYSETAK today announced positive topline results from its randomized doubleblind placebocontrolled multipledose Phase 2b trial evaluating TAK279 an investigational oral allosteric tyrosine kinase 2 TYK2 inhibitor with next generation selectivity in people with active psoriatic arthritis. ....